Εκπαιδευτικά
Λίστα αντικειμένων
Venetoclax Gets Breakthrough-Therapy Designation for
AML
At 12-month follow-up, the overall response rate was 44 percent
(complete remission, n=4; complete remission without complete
marrow recovery, n=4; resistant disease, n=8; death before
evaluation, n=2).
FDA Approves Combination Daunorubicin and Cytarabine for
High-Risk AML
The drug was approved based on...
Wediscussed the incidence and diagnosis of IDH mutations in AML.
The new approved drug may prove very helpful for these patients
Presenter: Spyridonidis
Participants: all medical staff
The US Food and Drug Administration (FDA) has approved enasidenib
(Idhifa) for the treatment of relapsed or refractory...
Extended analysis of the fiorst randomized ATG trial in BMT.
Presenter: Spyridonidis
Participants: All medical staff
Excellent paper by John Dicks group published in Nature. The
study identifies the reasosn why some aptrients relapse also
amny years after chemothertpay or allogheneic BMT.
Presenter: Spyridonidis
Participants: All medical staff
An intersting study showed a correaltion between CHIP and
atherpscleorosis.
We discussed the CHIP.
Presenter Spyridonidis
Participants: all medical staff
Στα πλαίσια του εκπαιδευτικού προγράμματος, θα γίνει ενημέρωση
την Τρίτη 13/6/2017, ώρα 13:30μ.μ. στα γραφεία της ΜΜΜΟ, από
εκπρόσωπο της εταιρίας Novartis, για το φάρμακο Μιντοσταυρίνη.
Το φάρμακο έχει πάρει έγκριση για εισαγωγή ασθενών στο Ομαδικό
Πρόγραμμα Πρώιμης Πρόσβασης από τον ΕΟΦ καθώς επίσης...
4 cases of CNS lymphjoma and testicular cancer with CNS disease
which responded to PD1 blockade. Clinical reports whith
mechanistivc insights
Presenter : Spyridonidis
Participants: All medial staff
A presentation provided by Abbvie describing the mechanism of
action of venetoclax.
PArticipants: All medical staff
Presnter: Spyridonidis Participants: all medical staff
Presenter: Spyridonidis
Participants: all medical staff
Presenter: Spyridonidis
Participants: all medical staff
Presenter: Spyridonidis
Participants: All medical staff
Presenter: Spyridonidis
Participants: all medical staff
MSD presented us the new data on posaconazole (iv and tbl
formulation) as well as new data on two antibtiotics against Gram
neg and Gram post bacteria(Sivextro, Zerbaxa)
Presenter: Efi Mintzia Brand & Customer ManagerMSD
Participants: all medical staff, Prof. Marangos
An excellent approach on how one could make decisions on
transplant or not to transplant (and when) in AML
patients.
Presenter: Spyridonidis
Participants: all medical staff
We discussed the clinical significance of AML mutations which
now can be detected with NGS AML panel. detected muations can be
used for prognosis, for targeted therapy or prediction fo response
to current therpaies.
Presenter: Spyridondis
Participants: all medical staff
NGS analysis can nowadays detect new mutations in AML. We
discuss their prognostic and therpauetic implications
Presenter: Spyridonidis
Participants: all medical staff
We discusssed the curretn progresses in cancer immunotherpay and
the way that we could overcome the primary, adaptive and aquired
resistance
Presenter: Spyridonidis
Participants: all medical staff
To answer whether a VUD or haplo or moreover sibling is the best
donmor, we need other tools beyond classical HAL which could
predict GvHD and GvL beter. We presented two intersting studies
using genome wide analysis for minor HALa and cimputerized epitope
prediction...
Βρέθηκαν 414 αποτελέσματα. Σελίδα 17 από 21